An overview of Chagas disease treatment.
Chagas disease (American trypanosomiasis) is endemic in 21 countries of the Americas, where control is largely focused on elimination of the domestic insect vectors (Triatominae) coupled with measures to extend and improve the screening of blood donors in order to avoid tranfusional transmission. Through national programmes and multinational initiatives coordinated by WHO-PAHO, much has been accomplished in these domains in terms of reducing transmission. Attention now turns to consolidating the successes in interrupting transmission, and improved treatment for those already infected and those who may become affected in the future. This article, based on technical discussions at the "Epidemiological and Sociological Determinants of Chagas Disease, Basic Information to Establish a Surveillance and Control Policy " meeting in Rio de Janeiro, is designed to open the debate on appropriate strategies for continuation of the successful initiatives against Chagas disease.
Jannin
Jean
J
Innovative & Intensified Disease Management, Neglected Tropical Diseases, WHO, Geneva, Switzerland. janninj@who.int
Villa
Luis
L
D014355:Chagas Disease / Q000188:drug therapy*; D006297:Health Services Accessibility; D006801:Humans; D007391:International Cooperation; D009547:Nifurtimox / Q000627:therapeutic use*; D009593:Nitroimidazoles / Q000627:therapeutic use*; D010175:Pan American Health Organization; D014344:Trypanocidal Agents / Q000627:therapeutic use*
D009593:Nitroimidazoles; D014344:Trypanocidal Agents; D009547:Nifurtimox; C009999:benzonidazole